Nuevas estrategias y generaciones de analgésicos opioides¿qué se está investigando?

  1. Esperanza Regueras 1
  2. Luis Miguel Torres 2
  3. Ignacio Velázquez 3
  1. 1 Universidad de Navarra
    info

    Universidad de Navarra

    Pamplona, España

    ROR https://ror.org/02rxc7m23

  2. 2 Hospital Puerta del Mar, Cádiz
  3. 3 Hospital de Guadix
Mostrar afiliaciones +
Revista:
MPJ Multidisciplinary Pain Journal

ISSN: 2697-2263

Año de publicación: 2023

Número: 1

Tipo: Artículo

DOI: 10.20986/MPJ.2022.1030/2022 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: MPJ Multidisciplinary Pain Journal

Resumen

Los fármacos opioides son indispensables en el tratamiento del dolor moderado-intenso, sin embargo, los efectos adversos pueden limitar su uso especialmente en el tratamiento del dolor crónico. Es de vital importancia encontrar nuevas alternativas terapéuticas que ofrezcan un mejor perfil de seguridad sin reducir la eficacia. En esta breve revisión explicamos cuales son las estrategias de investigación que se están siguiendo para obtener una nueva generación de fármacos que actuando sobre el sistema opioide endógeno ofrezca un mejor perfil de eficacia-seguridad.

Referencias bibliográficas

  • Roehr B. Trump declares opioid public health emergency but no extra money. BMJ. 2017;359:j4998.
  • McCarthy M. US declares opioid epidemic a “national emergency”. BMJ. 2017;358:j3881.
  • Bonnie RJ, Kesselheim AS, Clark DJ. Both Urgency and Balance Needed in Addressing Opioid Epidemic: A Report From the National Academies of Sciences, Engineering, and Medicine. JAMA. 2017;318(5):423-4.
  • Kirson NY, Scarpati LM, Enloe CJ, Dincer AP, Birnbaum HG, Mayne TJ. The Economic Burden of Opioid Abuse: Updated Findings. J Manag Care Spec Pharm. 2017;23(4):427-45.
  • Pollack HA. So Prescription Opioid Disorders are a $78.5 Billion Problem. Med Care. 2016;54(10):899-900.
  • Meyer JS, Quenzer LF. Psychopharmacology, drugs, the brain and behavior. 2.nd edition. Oxford: University Press; 2018.
  • O’Brien T, Christrup LL, Drewes AM, Fallon MT, Kress HG, McQuay HJ, et al. European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain. 2017;21(1):3-19.
  • Access to Pain Management: Declaration of Montreal [Internet]. IASP-PAIN.ORG; 2010 [accedido el 10 de octubre de 2020]. Disponible en: https://www.iasp-pain.org/DeclarationofMontreal.
  • Morone NE, Weiner DK. Pain as the fifth vital sign: exposing the vital need for pain education. Clin Ther. 2013;35(11):1728-32. DOI: 10.1016/j.clinthera.2013.10.001.
  • Campbell JN. APS 1995 Presidential address. Pain Forum. 1996;5(1):85-8.
  • Regueras E, Torres L, Velázquez I. Recomendaciones de práctica clínica de la Sociedad Española Multidisciplinar de Dolor (SEMDOR) para el buen uso médico de los opioides de prescripción en el tratamiento del dolor crónico no oncológico. MPJ. 2022. DOI: 10.20986/mpj.2022.1024/2022.
  • Regueras E, López J. Prescripciones de opioides en España entre 2019 y 2020: qué especialidades médicas lo están prescribiendo y en qué indicaciones. MPJ. 2021;1:5-12.
  • Varga BR, Streicher JM, Majumdar S. Strategies towards safer opioid analgesic- A review of old and upcoming targets. Br J Pharmacol. 2021;10.1111/bph.15760.
  • Faouzi A, Varga BR, Majumdar S. Biased Opioid Ligands. Molecules. 2020;25(18):4257.
  • Siuda ER, Carr R, Rominger DH, Violin JD. Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics. Curr Opin Pharmacol. 2017;32:77-84.
  • Li J, Csakai A, Jin J, Zhang F, Yin H. Therapeutic Developments Targeting Toll-like Receptor-4-Mediated Neuroinflammation. ChemMedChem. 2016;11(2):154-65.
  • Kaski SW, White AN, Gross JD, Siderovski DP. Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review. Anesth Analg. 2021;132(2):406-19.
  • Briggs SL, Rech RH, Sawyer DC. Kappa Antinociceptive Activity of Spiradoline in the Cold- Water Tail-Flick Assay in Rats. Pharmacol Biochem Behav. 1998;60(2):467-72.
  • Negus SS, Schrode K, Stevenson GW. Micro/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability. Exp Clin Psychopharmacol. 2008;16(5):386-99.
  • Khotib J, Narita M, Suzuki M, Yajima Y, Suzuki T. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors. Neuropharmacology. 2004;46(4):531-40.
  • Field MJ, Carnell AJ, Gonzalez MI, McCleary S, Oles RJ, Smith R, et al. Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain. Pain. 1999;80(1-2):383-9.
  • Inui S. Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol. 2015;8:249-55.
  • Davis MP, Fernandez C, Regel S, McPherson ML. Does nalbuphine have a niche in managing pain? J Opioid Manag. 2018;14(2):143-51.
  • Raehal KM, Walker JK, Bohn LM. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther. 2005;314(3):1195-201.
  • Singla NK, Skobieranda F, Soergel DG, Salamea M, Burt DA, Demitrack MA, Viscusi ER. APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty. Pain Pract. 2019;19(7):715-31.
  • Fujita W, Gomes I, Sullivan MD. Discovery of endogenous opioid systems: what it has meant for the clinician’s understanding of pain and its treatment. Pain. 2017;158(12):2290-300.
  • Milan-Lobo L, Enquist J, van Rijn RM, Whistler JL. Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism. PLoS One. 2013;8(3):e58362.
  • Kabli N, Nguyen T, Balboni G, O’Dowd BF, George SR. Antidepressant-like and anxiolytic-like effects following activation of the μ-δ opioid receptor heteromer in the nucleus accumbens. Mol Psychiatry. 2014;19(9):986-94.
  • Gomes I, Fujita W, Gupta A, Saldanha SA, Negri A, Pinello CE, et al. Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci U S A. 2013;110(29):12072-7.
  • Faouzi A, Uprety R, Gomes I, Massaly N, Keresztes AI, Le Rouzic V, et al. Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template. J Med Chem. 2020;63(22):13618-37.
  • Burford NT, Traynor JR, Alt A. Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications. Br J Pharmacol. 2015;172(2):277-86.
  • Bisignano P, Burford NT, Shang Y, Marlow B, Livingston KE, Fenton AM, et al. Ligand-Based Discovery of a New Scaffold for Allosteric Modulation of the μ-Opioid Receptor. J Chem Inf Model. 2015;55(9):1836-43.
  • Burford NT, Clark MJ, Wehrman TS, Gerritz SW, Banks M, O’Connell J, et al. Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor. Proc Natl Acad Sci U S A. 2013;110(26):10830-5.
  • Hua S, Cabot PJ. Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain condition. Pain Physician. 2013 May-Jun;16(3):E199-216Effects. Front Pharmacol. 2018;9:1388.
  • Nehoff H, Parayath NN, Domanovitch L, Taurin S, Greish K. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int J Nanomedicine. 2014;9:2539-55.
  • Hua S, Cabot PJ. Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain condition. Pain Physician. 2013;16(3):E199-216.
Fuente de los datos: Dialnet